Commodity Channel Index
|Bid||0.00 x 800|
|Ask||0.00 x 1800|
|Day's Range||91.08 - 97.10|
|52 Week Range||39.11 - 97.10|
|Beta (5Y Monthly)||1.28|
|PE Ratio (TTM)||70.53|
|Earnings Date||Jul 30, 2020 - Aug 03, 2020|
|Forward Dividend & Yield||N/A (N/A)|
|1y Target Est||86.17|
Emergent Biosolutions (EBS) closed at $94.23 in the latest trading session, marking a -0.26% move from the prior day.
Is (EBS) Outperforming Other Medical Stocks This Year?
Emergent (EBS) inks deals with multiple companies to provide manufacturing services for helping them develop COVID-19 vaccine.
The midcap drugmaker said Wednesday it would collaborate with the Mount Sinai Health System to test a drug derived from blood plasma taken from recovered Covid-19 patients.
Emergent BioSolutions Inc said on Wednesday it would jointly develop and run trials for its antibody product derived from plasma of recovered COVID-19 patients as a potential treatment with the Mount Sinai Health System. Under the partnership, which also includes biotech company ImmunoTek Bio Centers, Emergent will conduct a study on high-risk frontline healthcare workers and military personnel taking the experimental therapy within 72 hours after a possible exposure to the coronavirus. The clinical research will evaluate if treatment with Emergent's antibody product will help protect high-risk individuals and limit the spread of COVID-19.
The Mount Sinai Health System, Emergent BioSolutions (EBS), and ImmunoTek Bio Centers today announced that they will collaborate to develop, manufacture, and conduct clinical trials to evaluate Emergent’s COVID-19 hyperimmune globulin product, COVID-HIG, including a post-exposure prophylaxis (PEP) study on health care providers at high risk of COVID-19 infection and other high-risk populations, with $34.6 million in funding from the U.S. Department of Defense’s (DOD) Joint Program Executive Office for Chemical, Biological, Radiological, and Nuclear Defense (JPEO-CBRND). Located in New York City, one of the early epicenters of the outbreak, Mount Sinai has experience treating more than 10,000 COVID-19 cases and was among the very first in the United States to initiate a convalescent plasma program in late March.
The current health scare drives market volatility and calls for investment in consumer staples, healthcare and IT sectors for stable returns.
Emergent BioSolutions (EBS) extends a five-year deal with J&J to provide its CDMO services to produce the drug substance of the latter's COVID-19 vaccine candidate. Shares rise.
As of late, it has definitely been a great time to be an investor in Emergent BioSolutions
The U.S. government has awarded Novavax Inc $1.6 billion to cover testing, commercialization and manufacturing of a potential coronavirus vaccine in the United States, with the aim of delivering 100 million doses by January 2021. The award is the biggest yet from "Operation Warp Speed", the White House program aimed at accelerating access to vaccines and treatments to fight the coronavirus that causes COVID-19. "What this Warp Speed award does is it pays for production of 100 million doses, which would be delivered starting in the fourth quarter of this year, and may be completed by January or February of next year," Novavax Chief Executive Stanley Erck told Reuters.
Shares of Emergent BioSolutions Inc. were up 1.1% in premarket trading on Monday after it announced a five-year deal with Johnson & Johnson to manufacture the drug substance for the drugmaker's still-investigational COVID-19 vaccine. J&J will pay $480 million for two years of Emergent's contract development and manufacturing services. The two companies had previously announced in April a deal to reserve manufacturing capacity for J&J's vaccine candidate. Emergent has also announced coronavirus vaccine manufacturing deals with AstraZeneca , Novavax and Vaxart Inc. as part of a new strategy to build out manufacturing capacity for COVID-19 vaccines before they have proven their efficacy or safety. Emergent's stock has gained 55.8% since the start of the year. The S&P 500 , in comparison, has declined 3.1%.
Under the deal, starting next year Emergent will provide large-scale manufacturing services to produce the drug substance over five years, with the first two years valued at about $480 million. The news follows a $135 million deal struck by the two companies in April, to use Emergent's manufacturing facilities to speed up the development and production of its vaccine candidate.
Emergent BioSolutions Inc. (EBS) today announced a five-year manufacturing services agreement with Janssen Pharmaceuticals, Inc., one of the Janssen Pharmaceutical Companies of Johnson & Johnson, for large-scale drug substance manufacturing for Johnson & Johnson’s investigational SARS-CoV-2 vaccine, Ad26.COV2-S, recombinant based on the AdVac® technology. Emergent will provide contract development and manufacturing (CDMO) services to produce drug substance at large scale over five years, valued at approximately $480 million for the first two years.
Shares of Emergent Biosolutions (NYSE: EBS) and Regeneron (NASDAQ: REGN) have risen sharply in 2020 thanks to potential coronavirus drugs in development, but that's where their similarities end. Is Emergent, a company with government contracts to produce vaccines for other drugmakers, a better stock to buy now than Regeneron, a biotechnology pioneer with several blockbuster drugs under its belt? Over the past decade, Emergent Biosolutions has become the U.S. government's favorite contractor for infectious disease catastrophe preparation services.
This biotech has emerged as the manufacturing partner of choice for companies developing COVID-19 vaccines.
These five biotech stocks have already gone on heaters of 30% or more in 2020, and all of them still have plenty of upside to spare.
Amgen (AMGN) saw a big move last session, as its shares jumped more than 8% on the day, amid huge volumes.
Ultragenyx (RARE) saw a big move last session, as its shares jumped more than 8% on the day, amid huge volumes.
Emergent BioSolutions has become the go-to manufacturing partner for companies looking to develop vaccines for the coronavirus.
Inovio Pharmaceuticals Inc. has yet to share results from the Phase 1 trial for its COVID-19 vaccine candidate, but has already received millions of dollars in funding to scale up manufacturing capacity.
Vertex (VRTX) is seeking approval in Europe for its triple combo pill, Kaftrio in combination with Kalydeco to treat cystic fibrosis in patients aged 12 and older with most common genotypes.
The novel coronavirus pandemic has swept away several industries but has been a bit of a blessing for the biotech sector. iBio (NYSEMKT:IBIO) is one company that is benefiting from the hype surrounding the push for a vaccine, as iBio stock gained 490% this year.Source: Shutterstock As I discussed in my previous article, iBio's propriety technology called "Fast Pharming" provides the company with a unique edge in the scalability of a potential vaccine. The plant-based production system helped iBio attract investments from a few institutional investors. However, several investors are currently in two minds about investing in a vaccine inventor or a manufacturer such as iBio.This factor, along with its weak balance sheet, top the primary concerns for iBio at this time. Let's look into these aspects in more detail.InvestorPlace - Stock Market News, Stock Advice & Trading Tips Impact of Fast Pharming I talked about Fast Pharming in-length in my previous article on iBio, however, it's best to go over it again to set up a strong premise.iBio's system combines vertical farming, automated hydroponics and glycan engineering technologies to scale up vaccines, antibodies, and other proteins. This streamlines the manufacturing system with greater consistency and efficiency. It's much quicker to grow more plants to scale up production and relatively inexpensive at the same time. * 10 Consumer Stocks to Buy to Ride the Post-Covid-19 WaveThe production system is currently a novelty in the industry. Also, it represents a significant competitive advantage for iBio to scale up production for the companies involved in creating a Covid-19 vaccine.The company is collaborating with several institutions, including the Beijing CC-Pharming, Infectious Disease Research Institute. However, iBio has not won a contract with a significant vaccine developer.Recently, Moderna (NASDAQ:MRNA) announced a partnership with Swiss company Lonza (OTCMKTS:LZAGY) to scale up production of its Covid-19 vaccine using a new mRNA technology. That makes it imperative for iBio to make some consequential moves now before it loses out on significant contracts. Financial ComparisonSource: Muslim Farooque One of the most impressive things about iBio has been its ability to gain a unique position in an industry with significant barriers to entry.From the table above, we can see that iBio has the lowest market cap compared to the three bigwigs in the biotech sector. Naturally, it has the lowest fixed and current assets in the group. In addition, its free cash flows and margins have been in the negative along with the rest of the industry.Meanwhile, iBio has done significantly better than its peers concerning revenue growth.The real figure to consider at this stage is the research and development expenditure for the four companies along with their internal resources. It is clear that iBio is at a significant disadvantage in this comparison. The company needs to consistently seek ways to pump in more cash. Look Ahead for IBIO StockDevelopers of the Covid-19 vaccine seem to be closing in on the trial phase. Global pharmaceutical giant Pfizer believes that the vaccine should be ready by October. However, that is the best-case scenario, and several experts believe that it could potentially take longer.Nevertheless, vaccine developers are now looking to form partnerships with biotech companies to scale the production of their vaccine candidates.I talked about how Moderna partnered with a Swiss biotech firm called Lonza to scale up production. Similarly, other biotech companies such as the German Vibalogics GmbH and the American Emergent BioSolutions (NYSE:EBS) recently made waves.iBio also made inroads recently. However, as we get closer to the final stages of the vaccine's development, iBio and other biotech companies will be looking to land contracts with the major vaccine developers.The companies with the most success are likely to attract the most attention from investors. iBio's Fast Pharming system could potentially play a huge role in its success going forward. The company estimates an impressive 500 million dose capacity for its Covid 19 vaccine. Bottom Line on iBio Stock iBio is in a robust position as we get closer to a Covid 19 vaccine. Its Fast Pharming system provides it a unique stability technology that could set it apart. It is time for the company to score big with some major vaccine developers as we get closer to the October window.You could play the waiting game to see which manufacturers are making the most waves in the upcoming weeks, but I believe that iBio has excellent potential. And, now is a great time to grab the stock at a discount.As of this writing, Muslim Farooque did not hold a position in any of the aforementioned securities. More From InvestorPlace * Why Everyone Is Investing in 5G All WRONG * America's 1 Stock Picker Reveals His Next 1,000% Winner * Revolutionary Tech Behind 5G Rollout Is Being Pioneered By This 1 Company * Radical New Battery Could Dismantle Oil Markets The post iBio Is in a Healthy Position With Covid-19 Vaccine Push appeared first on InvestorPlace.
From deploying experts amid global travel restrictions to managing extreme storage conditions, and even inventing new kinds of vials and syringes for billions of doses, the path is strewn with formidable hurdles, according to Reuters interviews with more than a dozen vaccine developers and their backers. Any hitch in an untested supply chain - which could stretch from Pune in India to England's Oxford and Baltimore in the United States - could torpedo or delay the complex process. Col. Nelson Michael, director of the U.S. Army's Center for Infectious Disease Research who is working on the government's "Warp Speed" project to deliver a vaccine at scale by January, said companies usually have years to figure this stuff out.